B-RAF mutations are a rare event in pituitary adenomas

Journal of Endocrinological Investigation

Volumn 30, Issue 1, 2007, Pages

  De Martino, I ^a   Fedele, M ^a   Palmieri, D ^a   Visone, R ^a   Cappabianca, P ^a   Wierinckx, A ^b   Trouillas, J ^b   Fusco, A ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b University of Medicine   (France)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

B RAF; Gene mutation; NFPA; Pituitary adenomas; V600E

Indexed keywords

B RAF KINASE; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; RAS PROTEIN;

ARTICLE; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; EXON; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSECTOMY; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POINT MUTATION; POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; TUMOR BIOPSY;

EID: 33947539007     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347386     Document Type: Article

References (13)

1. Yu R, Melmed S. Oncogene activation in pituitary tumors. Brain Pathol 2001, 11: 328-41.
2. Spada A, Vallar L, Faglia G. G-proteins and hormonal signalling in human pituitary tumors: genetic mutations and functional alterations. Front Neuroendocrinol 1993, 14: 214-32.
3. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85: 707-20.
4. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994, 9: 1021-7.
5. Finelli P, Pierantoni GM, Giardino D, et al. The high mobility group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res 2002, 62: 2398-405.
6. Bettio D, Rizzi N, Giardino D, et al. Cytogenetic study of pituitary adenomas. Cancer Genet Cytogenet 1997, 98: 131-6.
7. Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002, 21: 3190-8.
8. Fedele M, Visone R, De Martino I, et al. HMGA2 induces tumorigenesis by enhancing E2FI activity. Cancer Cell 2006, 9: 459-71.
9. Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 1994, 78: 842-6.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the B-RAF gene in human cancer. Nature 2002, 417: 949-54.
11. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2002, 6: 313-9.
12. Busca R, Abbe P, Mancoux F, et al. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 2000, 19: 2900-10.
13. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-B-RAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005, 115: 94-101.